Abstract
The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Current Cancer Therapy Reviews
Title:Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Volume: 9 Issue: 4
Author(s): Mark J. McKeage, Phillip Shepherd, Masato Yozu and Donald R. Love
Affiliation:
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Abstract: The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Export Options
About this article
Cite this article as:
McKeage J. Mark, Shepherd Phillip, Yozu Masato and R. Love Donald, Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418093822
DOI https://dx.doi.org/10.2174/157339470904140418093822 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets The Application of Nanomaterials in Stem Cell Therapy for Some Neurological Diseases
Current Drug Targets Astrocytes as a 5-HT2B-Mediated SERT-Independent SSRI Target, Slowly Altering Depression-Associated Genes and Function
Current Signal Transduction Therapy Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry